Orbimed Advisors Llc Portfolio Shifts in Q2 2026: Focus on Biotech Gains

Orbimed Advisors Llc's portfolio activity for Q2 2026 is dominated by shifts within its highly focused Healthcare sector. The investment firm maintains a nearly exclusive allocation to this sector, with all disclosed holdings falling under it or being categorized as unknown.

The second quarter saw Orbimed Advisors establish several new positions and increase stakes in existing holdings. Notably, the firm initiated significant investments in AURA BIOSCIENCES INC (AURA), SAVARA INC (SVRA), PRELUDE THERAPEUTICS INC (PRLD), ARCUTIS BIOTHERAPEUTICS INC (ARQT), COGENT BIOSCIENCES INC (COGT), and Q32 BIO INC (QTTB). These additions, detailed below, reflect Orbimed's continued interest in emerging biotech companies.

New Positions & Significant Increases:

• AURA BIOSCIENCES INC (AURA): Orbimed added a substantial position with an increase of over 100% in shares, representing approximately $23.7M invested at quarter-end.
• SAVARA INC (SVRA): Shares increased significantly by more than fivefold, adding around $24.4M to the portfolio value.
• PRELUDE THERAPEUTICS INC (PRLD): This position saw a nearly threefold increase in shares during Q2, contributing about $73.2M to Orbimed's holdings.
• Q32 BIO INC (QTTB): Shares jumped by approximately 83% compared to the previous quarter, adding roughly $52.6M at a portfolio allocation of just over 1.0%.
• COGENT BIOSCIENCES INC (COGT): Orbimed quintupled its position in COGT during Q2, investing approximately $65.1M and boosting the stake's value significantly.
• ARCUTIS BIOTHERAPEUTICS INC (ARQT): Shares increased fourfold, adding about $53.5M to the portfolio at a time when ARQT held roughly 1.0% of Orbimed's total assets.

In addition to these new positions, Orbimed also invested in TAYSHA GENE THERAPIES INC (TSHA), ZENTALIS PHARMACEUTICALS INC (ZNTL), and PROTARA THERAPEUTICS INC (TARA). These additions further diversify the firm's biotech focus within its Healthcare allocation.

Conversely, during Q2 2026, Orbimed Advisors reduced or exited several positions. The most significant reduction was in ENLIVEN THERAPEUTICS INC (ELVN), where shares decreased by approximately 14.86%. Other notable decreases include SIONNA THERAPEUTICS INC (SION) (-27.61%), TREVI THERAPEUTICS INC (TRVI) (-41.73%), RELMADA THERAPEUTICS INC (RLMD) (-23.0%), and BOSTON SCIENTIFIC CORP (BSX) (-37.74%).

Decreases & Portfolio Shifting:

• ENLIVEN THERAPEUTICS INC (ELVN): Orbimed sold shares, resulting in a nearly two-thirds reduction in the stake's value during Q2.
• SIONNA THERAPEUTICS INC (SION): The position saw a substantial decrease of about 27.61% compared to the previous quarter.
• TREVI THERAPEUTICS INC (TRVI): Shares decreased by roughly 41.73%, indicating a significant reduction in exposure for this company.
• PROTARA THERAPEUTICS INC (TARA): Although shares increased, the overall portfolio allocation percentage remained low at just over 0.16%.
• NEUMORA THERAPEUTICS INC. (NMRA): Shares increased but the position's impact on the total portfolio was minimal, adding only about $3.6M in value.

The data shows that Orbimed Advisors is actively managing its concentrated Healthcare portfolio, making significant additions while strategically reducing exposure to certain companies within the sector during Q2 2026.